Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Genelux logo — company profile

Genelux

Founded 2001 United States Westlake Village, United States 34 employees Post Ipo Equity Total: $98.98M Biopharma, Biotechnology +1

General Information

Company Name Genelux
Founded Year 2001
Location United States Westlake Village, United States +1
Founders / Decision Makers
Team member
Employees 34
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Genelux moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Genelux

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology firm founded in 2001 and based in the United States. The company operates at the forefront of the Biopharma, Biotechnology, and Health Care industries, focusing on oncolytic immunotherapy to improve patient outcomes in cases of challenging solid tumors.

Their proprietary ChoiceTM Discovery Platform underpins the development of a robust pipeline of therapies, with Olvi-Vec being their leading candidate currently undergoing a Phase 3 clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Beyond PRROC, Olvi-Vec is also in development for Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer.

Recently, Genelux secured a $27.50M Post-IPO Equity investment on 24 May 2024, further bolstering their pursuit of next-generation cancer therapies and reinforcing their commitment to innovative healthcare solutions.

Taxonomy: oncolytic immunotherapy, solid tumors, cancer treatment, clinical-stage biotech, viral therapy, immunotherapies, clinical trials, cancer research, cancer therapy, personalized medicine

Services & Products

Development of oncolytic immunotherapy
Clinical trial management
Expanded access programs

Target Customers

Cancer patients Healthcare professionals Clinical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 24 May 2024
Post-IPO Equity •••••• - 12 Jun 2023
Post-IPO Equity •••••• - 15 May 2023
Convertible Note •••••• 1
Investor
25 Sep 2020
Venture Round •••••• - 06 Jun 2012

Genelux Alternatives & Competitors

Genelux vs
OncXerna Therapeutics
OncXerna Therapeutics United States

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...

Series Unknown
8 employees
Biopharma, Biotechnology
Compare Genelux vs OncXerna Therapeutics
Genelux vs
Clearity
Clearity United States

For life with ovarian cancer.

19 employees
Biotechnology, Health Care
Compare Genelux vs Clearity
Genelux vs
Novocure
Novocure Switzerland

Patient-forward: Aspiring to make a difference in cancer

Post Ipo Debt
1384 employees
Biotechnology, Health Care
Compare Genelux vs Novocure

FAQ About Genelux

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different v...
Genelux was founded in 2001.
Genelux is headquartered in Westlake Village, United States.
Genelux operates in the following industries: Biopharma, Biotechnology, Health Care.
Genelux has approximately 34 employees.
Genelux has completed 5 funding rounds, raising a total of $98.98M. The latest funding stage is Post Ipo Equity.
Genelux offers: Development of oncolytic immunotherapy, Clinical trial management, Expanded access programs.
Top alternatives and competitors to Genelux include OncXerna Therapeutics , Clearity, Novocure, GeneMedicine, Kintara Therapeutics, Inc. NASDAQ: KTRA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genelux and OncXerna Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Genelux and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy